Drug Combination Details
| General Information of the Combination (ID: C29204) | |||||
|---|---|---|---|---|---|
| Name | Lithium NP Info | + | Pyrroloquinoline quinone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Alzheimer disease
[ICD-11: 8A20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p38 beta | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Male APP/PS1 transgenic mice and littermate wild type control were used in this study. | |||||
| Experimental
Result(s) |
This study demonstrated the efficacy of a novel AD therapeutic strategy targeting at multiple disease-causing mechanisms through the synergistic effects of microdose lithium and pyrroloquinoline quinone. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. Neurobiol Aging. 2014 Dec;35(12):2736-2745. | |||
